Gritstone bio wins $433 million US contract for COVID vaccine study

Gritstone bio (GRTS.O) on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its self-amplifying mRNA COVID-19 vaccine candidate.